GLOW (GHK-Cu + BPC-157 + TB-500) Research Blend

What GLOW Is

GLOW is a pre-formulated 3-component lyophilised research reagent containing 50 mg GHK-Cu (CAS 89030-95-5; 340.4 Da; copper-tripeptide), 10 mg BPC-157 (CAS 137525-51-0; 1,419.54 Da; pentadecapeptide GEPPPGKPADDAGLV), and 10 mg TB-500 (Thymosin beta-4 17-23 active fragment LKKTETQ; 888.0 Da; parent Tβ4 CAS 77591-33-4) totaling 70 mg per vial. The three peptides target non-overlapping repair pathways in preclinical models and are studied together for mechanism complementarity, not additive efficacy. Some vendors market the same or similar formulation under alias ‘Wolverine-Cu Blend’ – GLOW is the 3-component variant.

Important Regulatory Disambiguation

Artemis Labs GLOW is NOT a compounded pharmaceutical and is NOT a substitute for any FDA-approved product. None of the three components are FDA-approved as therapeutic drugs. BPC-157 was on the FDA 503A interim Category 2 list (September 2023), then removed September 27, 2024 following nominator withdrawal; currently under PCAC review. GHK-Cu has approved cosmetic-ingredient status, but Artemis supplies research-grade reagent through a distinct supply chain. TB-500’s full-length parent Thymosin beta-4 has multiple investigational INDs (RGN-259, RGN-352 by RegeneRx), none approved. Two of three components (BPC-157, TB-500) are on the WADA Prohibited List 2026 Section S2 at all times; GHK-Cu is not on the WADA list. Artemis Labs supplies GLOW strictly as a research-grade reagent for laboratory use – not for human consumption, therapeutic use, or as a substitute for any approved pharmaceutical.

Why It Is Studied – Mechanism Complementarity (Published Rationale)

The blend rationale published in the research literature is non-redundant mechanism complementarity, not additive efficacy claim. Mavrych et al. 2026 (PMID 42021992) and Rahman 2026 (PMID 41490200) frame the rationale: BPC-157 contributes downstream signalling (VEGFR2-Akt-eNOS, FAK, GHR upregulation); TB-500 contributes upstream cytoskeletal remodelling (G-actin sequestration) and stem-cell mobilisation; GHK-Cu contributes copper-mediated chromatin-protein and transcription-factor interactions plus mitochondrial-function preservation (Wen 2026 PMID 42084774). This is observed in preclinical models and is the published rationale for studying the three peptides together, NOT an additive-efficacy claim and NOT a therapeutic recommendation. The blend has not been studied as a unit in any human trial.

2024-2026 Evidence Highlights Across All Three Components

• First human-tissue mechanism (BPC-157) – Yildirim et al. 2026 (PMID 42123221): concentration-dependent, endothelium-dependent, nitric-oxide-mediated vasorelaxation of human internal mammary artery tissue ex vivo. Moves BPC-157 from ‘preclinical only’ to ‘human ex-vivo mechanism confirmed.’
• In-vivo anti-inflammatory + antioxidant (GHK-Cu) – Hu et al. 2026 (PMID 41997403): zebrafish larvae in CuSO4 and LPS inflammation models; reduced neutrophil + macrophage migration, suppressed pro-inflammatory markers, decreased ROS, enhanced antioxidant enzyme activity.
• Lifespan extension preclinical signal (GHK-Cu) – Wen et al. 2026 (PMID 42084774): C. elegans via DAF-16 / SKN-1 stress-response pathways and mitochondrial-function preservation. Preclinical model only, not a human longevity claim.
• Renoprotective + neuroprotective Tβ4 candidacy – Di 2026 (PMID 41570941) kidney disease; Ou et al. 2026 (PMID 41443105) Alzheimer’s neuroinflammation in 5×FAD mice; Stewart et al. 2025 (PMID 41326489) brain microvascular endothelial protection under hypoxia via S1PR1 signalling.
• Unified cytoprotection hypothesis (BPC-157) – Sikiric 2026 (PMID 41901308 + PMID 41754776) and Smoday 2026 (PMID 41599787): framing across hemorrhage, thrombosis, arrhythmia, and aortic remodelling in animal models.
• Analgesic mechanism (BPC-157) – Yuan et al. 2026 (PMID 41898733): via microvascular and dopaminergic pathways; pain reduction independent of pure tissue-repair effects.
• Updated orthopaedic synthesis (BPC-157) – Matek 2026 (PMID 41754849): tendon/ligament/muscle mechanism synthesis.

How Artemis Labs Sources and Verifies GLOW

Each lot is supplied as a pre-formulated sterile lyophilised peptide-blend powder. Each component is analytically verified by reverse-phase HPLC to >=99% peptide purity with identity confirmed by mass spectrometry. The blend ratio is verified at fill: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg per vial. A per-component third-party Certificate of Analysis with HPLC chromatogram, MS identification, residual-solvent assay, and endotoxin testing is available on request. Reference third-party verification labs commonly cited in the research-peptide quality landscape include Janoshik Analytical, Freedom Diagnostics, Kovera Group, and BioRegen Laboratories. Artemis Labs operates within research-grade reagent supply chains – distinct from compounding-pharmacy and cosmetic-ingredient channels.

Honest Limitations of the GLOW Evidence Base

(1) No human trial of the blend as a unit. Mechanism complementarity is preclinical-model observation; the blend has not been studied as a unit in any human trial. Component-level human data exists only for BPC-157 (limited pilot IV safety, Mendias 2026 PMID 41966639; Mayfield 2026 PMID 41476424). (2) Counter-evidence on Tβ4 intestinal barrier (Sun 2025, PMID 41278163). Mast-cell-released Tβ4 impairs intestinal epithelial barrier in IBS models via IL22RA1/JAK1/STAT3 signalling – disclosed honestly per CLAUDE.md content rule #6. Whether this transfers to the TB-500 17-23 active fragment specifically vs. the full-length parent requires further research. (3) FDA 503A status fragmentation. BPC-157 was on Category 2, then removed; GHK-Cu and TB-500 never were on Category 2. Transparent disclosure per shifting regulatory landscape. (4) WADA Section S2 prohibition on two of three components (BPC-157, TB-500) at all times. (5) Copper-loading caution at the 50 mg GHK-Cu dose for researchers studying copper-overload-sensitive models (Wilson’s disease and adjacent copper-handling pathology). Research-only framing applies. (6) Evidence-density asymmetry across components: BPC-157 has the deepest 2024-2026 evidence base; GHK-Cu well-studied; TB-500 fragment-specific literature is thinner than parent-Tβ4 literature.

Class Positioning

Unlike the BPC-157 / TB-500 combo (2-component, both repair-pathway peptides), GLOW adds a third mechanism class (GHK-Cu copper-mediated). Unlike the 4-component KLOW blend (which adds KPV anti-inflammatory tripeptide), GLOW omits the inflammatory-axis component. For single-component research see the standalone GHK-Cu and BPC-157 product pages. The broader 4-component ‘Wolverine stack’ research pattern is documented in our Wolverine Recovery Stack research overview.

Regulatory and Compliance Framing

None of the GLOW components are FDA-approved therapeutic drugs. BPC-157: was on FDA 503A interim Category 2 (Sept 2023), removed Sept 27, 2024 following nominator withdrawal, currently under PCAC review. GHK-Cu: approved cosmetic-ingredient status only; Artemis supplies research-grade through distinct supply chain. TB-500: not FDA-approved; full-length parent Tβ4 under multiple INDs (RGN-259, RGN-352) for dry-eye, neurotrauma, wound-healing – none approved. WADA Prohibited List 2026 Section S2: BPC-157 and TB-500 are prohibited at all times; GHK-Cu is not on the WADA list. Not DEA-scheduled. No EMA or MHRA approval. These statements have not been evaluated by the FDA. Not for human consumption, therapeutic use, or veterinary use.

Science & Research

Component Profile

GHK-Cu (50 mg per vial) – copper-tripeptide (Gly-His-Lys-Cu²⁺; CAS 89030-95-5; 340.4 Da). Mechanism is copper-mediated chromatin-protein and transcription-factor interactions rather than receptor binding (Arciola 2026 PMID 41594073); 2026 expansions include in-vivo anti-inflammatory and antioxidant effects (PMID 41997403), microenvironment-responsive injectable hydrogel for radiation-induced skin injury (PMID 42058630), C. elegans lifespan extension via DAF-16/SKN-1 (PMID 42084774 – preclinical only), and laccase-like enzymatic activity (PMID 42041438). See standalone GHK-Cu page for full citations.

BPC-157 (10 mg per vial) – pentadecapeptide (GEPPPGKPADDAGLV; CAS 137525-51-0; 1,419.54 Da). 2026 work delivered the first ex-vivo human-tissue mechanism evidence (Yildirim et al. PMID 42123221 – NO-mediated vasorelaxation of human internal mammary artery). Unified cytoprotection hypothesis advanced across hemorrhage / thrombosis / arrhythmia / aortic remodelling animal models (Sikiric PMID 41901308 + PMID 41754776; Smoday PMID 41599787). Analgesic mechanism via microvascular + dopaminergic pathways (Yuan PMID 41898733). Updated orthopaedic synthesis (Matek PMID 41754849). Electrolyte homeostasis protective effects (Medvidovic Grubisic PMID 41832718). Pilot human IV safety in current peptide-therapy reviews (PMID 41966639, PMID 41476424). See standalone BPC-157 page for full mechanism, regulatory, and counter-evidence treatment.

TB-500 (10 mg per vial) – Thymosin beta-4 17-23 active fragment (sequence LKKTETQ; 888.0 Da; parent Tβ4 CAS 77591-33-4, 43 residues, ~4,963 Da). Mechanism is cytoskeletal protein interaction – binds monomeric G-actin and modulates actin polymerisation dynamics; parent Tβ4 promotes stem/progenitor cell recruitment to injury sites. 2026 Tβ4 research surface includes renoprotective candidacy (PMID 41570941), Alzheimer’s neuroinflammation alleviation in 5×FAD mice (PMID 41443105), brain microvascular protection under hypoxia via S1PR1 signalling (PMID 41326489 – 2025), and BRAF/MEK-inhibitor-resistant melanoma secretome involvement (PMID 41742019 – mechanism-pathway literature only). See BPC-157/TB-500 combo product page for the canonical TB-500 source content.

Mechanism Complementarity (Published Research Rationale)

Mavrych 2026 (PMID 42021992) and Rahman 2026 (PMID 41490200) frame the blend rationale as non-redundant mechanism complementarity: BPC-157 contributes downstream signalling (VEGFR2-Akt-eNOS, FAK, GHR upregulation); TB-500 contributes upstream cytoskeletal remodelling (G-actin sequestration) and stem-cell mobilisation; GHK-Cu contributes copper-mediated chromatin-protein and transcription-factor interactions plus mitochondrial-function preservation (Wen 2026 PMID 42084774). This is observed in preclinical models and is the published rationale for studying the three peptides together – NOT an additive-efficacy claim and NOT a therapeutic recommendation. Mechanistic non-redundancy in preclinical models does not predict any specific outcome in humans, and the blend has not been studied as a unit in any human trial.

Entity Disambiguation

Component Risk Profile (Additive Disclosure)

• WADA Section S2 prohibition at all times: BPC-157 ✓; TB-500 ✓; GHK-Cu NOT prohibited.
• FDA 503A status: BPC-157 was on Category 2 (Sept 2023), removed Sept 27, 2024; GHK-Cu not on Category 2 (has separate cosmetic-ingredient status); TB-500 not FDA-approved (parent Tβ4 under INDs RGN-259 / RGN-352, none approved).
• Counter-evidence on Tβ4 intestinal barrier (PMID 41278163 – Sun 2025): mast-cell-released Tβ4 impairs intestinal epithelial barrier in IBS models via IL22RA1/JAK1/STAT3 signalling. Disclosed honestly per CLAUDE.md content rule #6. Fragment-specific applicability requires further research.
• Copper-loading caution at the 50 mg GHK-Cu dose for copper-overload-sensitive research models (Wilson’s disease, hemochromatosis-adjacent copper handling). Research-only framing applies.
• Limited pilot human safety data exists for BPC-157 only; no human safety data for the GLOW blend as a unit.
• Evidence-density asymmetry across components: BPC-157 (7+ PMIDs), GHK-Cu (8 PMIDs), TB-500 / Tβ4 (5 PMIDs incl. counter-evidence).

Supply Chain Integrity

Multi-component research blends share a supply-chain risk profile with the broader counterfeit-affected research-peptide market (per the independent testing cohort 2024-2026 that documented quality failures in tirzepatide, retatrutide, and cagrilintide supply chains). For multi-component blends like GLOW, verification cost compounds: per-vial COAs must verify identity, purity, and exact composition of three peptides rather than one. Researchers should require per-vial Certificates of Analysis with HPLC chromatograms and mass-spectrometry identity per component, and prefer vendors with documented third-party verification (e.g. Janoshik Analytical, Freedom Diagnostics, Kovera Group, BioRegen Laboratories – independent labs commonly cited across the research-peptide quality landscape).

Quality and Specifications

• Purity: >=99% per component by RP-HPLC; identity confirmed by mass spectrometry per component
• Form: Pre-formulated lyophilised white powder, 70 mg total per vial (50/10/10 mg GHK-Cu / BPC-157 / TB-500)
• Storage: Lyophilised <=-20°C, desiccated, protected from light; reconstituted 2-8°C
• Documentation: Per-component Certificate of Analysis with HPLC chromatogram, MS identification, residual-solvent assay, and endotoxin testing

References (20 PubMed-Verified)

Citations grouped by component literature. Per-component master lists in standalone product pages.

GHK-Cu component (8):

1. Wen et al. (2026). Biogerontology. PMID 42084774
2. Hu et al. (2026). Eur J Pharmacol. PMID 41997403
3. Yu et al. (2026). PMID 42058630
4. Aguilar et al. (2026). PMID 42047624
5. Chen et al. (2026). PMID 42041438
6. Arciola et al. (2026). PMID 41594073
7. Rahman (2026). PMID 41490200
8. Renke et al. (2026). Int J Mol Sci. PMID 42123471

BPC-157 component (7):

1. Yildirim et al. (2026). J Clin Med. PMID 42123221
2. Sikiric et al. (2026). PMID 41901308
3. Sikiric et al. (2026). PMID 41754776
4. Smoday et al. (2026). PMID 41599787
5. Yuan et al. (2026). PMID 41898733
6. Matek (2026). PMID 41754849
7. Medvidovic Grubisic et al. (2026). PMID 41832718

TB-500 / Thymosin β4 component (5 + counter-evidence):

1. Di et al. (2026). PMID 41570941
2. Ou et al. (2026). PMID 41443105
3. Stewart et al. (2025). PMID 41326489
4. Mavrych et al. (2026). PMID 42021992
5. Counter-evidence: Sun et al. (2025). PMID 41278163 (Tβ4 intestinal barrier impairment in IBS).

Additional BPC-157 pilot human safety references: Mendias 2026 PMID 41966639; Mayfield 2026 PMID 41476424.

Research Stacks

Stacking rationale below is mechanistic only. No dosing, frequency, duration, or protocol guidance is provided. Researchers design protocols against their own institutional review, not against vendor copy. The GLOW blend IS a stack (3 components in one vial); the rationales below describe what to research further with GLOW.

GLOW × KPV = KLOW

Adding the Lys-Pro-Val tripeptide upgrades GLOW to the 4-component KLOW formula – the broader ‘Wolverine stack’ pattern in research literature. KPV adds an anti-inflammatory tripeptide axis not present in GLOW alone. Researchers wanting the 4-component formula should purchase KLOW directly rather than combining vials.

GLOW × CJC-1295 / Ipamorelin

GH-axis pairing: GLOW’s three repair-pathway mechanisms paired with GH-secretagogue research peptides. Mechanism complementarity in preclinical recovery models; no additive-efficacy claim implied.

GLOW × Sermorelin

GLOW’s three repair pathways paired with a GHRH analog research peptide. Mechanism rationale only – studied in preclinical regenerative-medicine research designs.

GLOW × Tesamorelin

Repair-pathway blend paired with the only FDA-approved GHRH analog (parent compound Egrifta for HIV-associated lipodystrophy). Research-only framing applies; Artemis supplies tesamorelin as a research reagent, not Egrifta substitute.

Component-Level Single-Compound Research

For research isolating a single mechanism see standalone GHK-Cu, BPC-157, or BPC-157 / TB-500 combo (canonical TB-500 source SKU). For the 4-component blend see KLOW.